a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States. Unraveling the Financial Story of Nevro Market Capitalization Analysis ...

Nevro Corp is a medical device company ... a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...

Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The firm had revenue of $96.60 million for the quarter, compared to the consensus estimate of $93.09 million.

In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a price target of $5.85. The company’s shares closed ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for Nevro ...